The FDA advisory vote that ended on July 24 was covered as a regulatory story. Wall Street read it as a revenue story. Within hours of the first tally, Hims & Hers stock jumped more than 10% intraday, analysts published market-size notes, and the phrase "peptide telehealth" started appearing in equity research for the first time.
The numbers attached to that reaction are worth understanding, because they describe the commercial shape of what a legal prescription channel for BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon would look like — and, by implication, what it would cost.
Research-context information only. BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon are research peptides sold for research purposes only. The market estimates, share prices, and regulatory timelines below come from public company filings, analyst notes, and press reporting. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
What Wall Street actually priced in
Leerink Partners analyst Michael Cherny called the committee outcome a positive catalyst and estimated the peptides under review could support roughly a $2.2 billion annual telehealth market, with Hims & Hers positioned to capture about 20% of it. Needham & Co ran a higher number on the same opportunity — up to $3.3 billion — and separately sized the broader addressable peptide market, including current grey-market and health-optimization use, at roughly $30 billion.
The share reaction tracked those notes rather than the regulatory substance. HIMS traded up more than 10% intraday on Thursday, July 23 — the day BPC-157, TB-500, and KPV each cleared 8-6 with one abstention and MOTS-c cleared 7-5 with two abstentions — before giving back most of the move to close around 3% higher at $32.74. It added another 1.13% to $33.11 the following session. The bear case was voiced too: Martin Shkreli publicly disclosed a short position against the move.
The reason a single telehealth company absorbed most of the attention is infrastructure. Hims acquired a California peptide manufacturing facility in February 2025, following earlier acquisitions of 503A compounding pharmacies in Ohio and Arizona and a 503B sterile facility in California. That stack — prescriber network, compounding pharmacy, peptide production — is the exact set of assets a 503A bulks-list addition would activate. Analysts were not pricing new science; they were pricing an existing supply chain finally having something legal to run through it.
Other platforms surfaced in the same commentary — Ro and the clinician-network infrastructure provider Wheel among them — though neither has announced a peptide program. Fortune's pre-vote analysis projected that once a legal channel opens, well-funded platforms would out-compete smaller operators within roughly six months.
The gap between the vote and a prescription pad
None of those revenue estimates are collectable yet, and the reason is procedural. A Pharmacy Compounding Advisory Committee recommendation is advisory. For any of the six recommended peptides to become legally compoundable, the FDA has to review the recommendation, decide whether to accept it, publish a proposed rule, open a public comment window, and then issue a final rule. The agency's own materials describe that sequence as running 12 months or longer, which pushes the earliest realistic legal-compounding date into 2027 and beyond. The FDA has declined to follow PCAC recommendations before.
There is a nearer-term regulatory date on the calendar as well: a separate decision on GLP-1 exclusions from 503B compounding was pushed to July 30, 2026. That one affects the compounded semaglutide and tirzepatide channel rather than the seven peptides voted on last week, but it is the next data point on how aggressively the agency intends to police compounded peptide supply. Our breakdown of that proposal is in the 503B GLP-1 compounding exclusion explainer.
What the prescription route would cost
No compounded pricing has been published for any of the six peptides, so any specific dollar figure circulating right now is speculation. What can be described is structure. A compounded prescription carries cost layers a research-use vial does not: a telehealth consultation fee, a licensed prescriber, a 503A pharmacy's sterile preparation and release testing, shipping under a pharmacy license, and the platform's own margin. Analyst models that produce a $2.2 billion market from a compound class currently sold in the grey market at low double-digit dollars per vial are, by construction, assuming a substantial per-unit premium.
The nearest historical comparison is compounded GLP-1s. When that channel was open, the same molecules were priced materially higher through telehealth programs than through research-use suppliers — a pattern documented across the crackdown coverage in our compounded GLP-1 alternatives breakdown. Whether that spread repeats for the recovery and longevity peptides is unknown, but the cost inputs are the same.
Affiliate disclosure: The Peptide Catalog earns a commission on purchases made through the vendor links below and in the comparison cards further down.
For anyone comparing today's market, per-mg pricing, COA documentation, and stock across the peptides in question are listed on the BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon vendor pages, with active vendor codes on the deals page.
